KR970703316A - 4-퀴놀리논 유도체 또는 그의 염(4-quinolinone derivative or salt thereof) - Google Patents
4-퀴놀리논 유도체 또는 그의 염(4-quinolinone derivative or salt thereof) Download PDFInfo
- Publication number
- KR970703316A KR970703316A KR1019960706750A KR19960706750A KR970703316A KR 970703316 A KR970703316 A KR 970703316A KR 1019960706750 A KR1019960706750 A KR 1019960706750A KR 19960706750 A KR19960706750 A KR 19960706750A KR 970703316 A KR970703316 A KR 970703316A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- substituted
- salt
- different
- same
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 125000005843 halogen group Chemical group 0.000 claims abstract 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 10
- -1 phenylsulfinyl group Chemical group 0.000 claims abstract 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 5
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract 5
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract 5
- 125000001424 substituent group Chemical group 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract 2
- 229910052757 nitrogen Chemical group 0.000 claims abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 208000014181 Bronchial disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- SQVWVIHFFKKWIM-UHFFFAOYSA-N 1-aminoquinolin-4-one Chemical class C1=CC=C2N(N)C=CC(=O)C2=C1 SQVWVIHFFKKWIM-UHFFFAOYSA-N 0.000 claims 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 108010083133 potassium channel protein I(sk) Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
본 발명은 하기 일반식(1)
[식 중, R1및 R2는 각각 같거나, 상이한 것으로서 수소원자; 할로겐 원자; 시아노기; 할로겐 원자로 치환되어도 좋은 저급 알킬, 저급 알킬술포닐, 저급 알킨술피닐, 저급 알킬티오 또는 저급 알콕시기; 또는 치환기를 가져도 좋은 페닐술포닐기, 페닐술피닐기 또는 페닐티오기를 나타내고; R3및 R4는 각각 같거나, 상이한 것으로서 수소 원자; 할로겐 원자로 치환되어도 좋은 저급 알킬, 또는 시클로 알킬; 또는 치환기를 가져도 좋은 피리딜, 푸라딜 또는 페닐기를 나타내거나, 또는 R3및 R4가 인접 탄소 및 질소원자와 함께 저급 알킬기로 치환되어도 좋은 4-, 5- 또는 6-원 복소환기를 형성하여도 좋다.]로 표시되는 4-퀴놀리논 유도체 또는 그의 염, 및 그 외에 이 화합물을 유효 성분으로 함유하는 의약 조성물. 이 화합물(1) 또는 그의 염은 우수한 칼륨 채널 활성화 작용을 갖고 있으며, 예를 들면, 순환기계 질환 및 기관기계 질환의 예방 및 치료약으로서 유용하다.
Description
4-퀴놀리논 유도체 또는 그의 염(4-QUINOLINONE DERIVATIVE OR SALT THEREOF)
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 다음 일반식(1)[식 중, R1및 R2는 각각 같거나, 상이한 것으로서 수소원자; 할로겐 원자; 시아노기; 할로겐 원자로 치환되어도 좋은 저급 알킬, 저급 알킬술포닐, 저급 알킨술피닐, 저급 알킬티오 또는 저급 알콕시기; 또는 치환기를 가져도 좋은 페닐술포닐기, 페닐술피닐기 또는 페닐티오기를 나타내고; R3및 R4는 각각 같거나, 상이한 것으로서 수소 원자; 할로겐 원자로 치환되어도 좋은 저급 알킬, 또는 시클로 알킬; 또는 치환기를 가져도 좋은 피리딜, 푸라딜 또는 페닐기를 나타내거나, 또는 R3및 R4가 인접 탄소 및 질소원자와 함께 저급 알킬기로 치환되어도 좋은 4-, 5- 또는 6-원 복소환기를 형성하여도 좋다.]로 표시되는 4-퀴놀리논 유도체 또는 그의 염.
- 제1항에 있어서, R1및 R2는 각각 같거나, 상이한 것으로서 수소 원자; 할로겐 원자; 시아노기; 1∼3개의 할로겐 원자로 치환되어도 좋은 탄소수 1∼6의 알킬, 알킬술포닐, 알킬술피닐, 알킬티오 또는 알콕시기; 페닐술포닐기, 페닐술피닐기 또는 페닐티오기를 나타내고; R3및 R4는 각각 같거나, 상이한 것으로시 수소 원자; 1∼3개의 할로겐 원자로 치환되어도 좋은 탄소수 1∼6의 저급 알킬, 또는 시클로알킬기; 또는 할로겐 원자, 히드록시기, 탄소수 1∼6의 알콕시기, 아릴옥시기, 아르알킬올시기, 니트록시, 아미노기, 시아노기, 니트로기, 탄소수 1∼6의 알킬아미노기, 탄소수 2∼12의 디알킬아미노기, 아릴기, 아미노술포닐기 또는 탄소수 1∼6의 알킬기로부터 선택된 기로 치환된 피리딜기, 푸라닐기 또는 페닐기를 나타내거나, 또는 R3및 R4가 인접탄소 및 질소원자와 함께 탄소수 1∼6의 알킬기로 치환되어도 좋은 2-옥소아제티딘, 2-옥소피롤리디닐, 또는 2-옥소피페리디닐기를 형성하여도 좋다.]로 표시되는 4-퀴놀리논 유도체 또는 그의 염.
- 하기 일반식(1)[식 중, R1및 R2는 각각 같거나, 상이한 것으로서 수소 원자; 할로겐 원자; 시아노기; 할로겐 원자로 치환되어도 좋은 저급 알킬, 저급 알킬술포닐, 저급 알킬술피닐, 저급 알킬티오 또는 저급 알콕시기; 또는 치환기를 가져도 좋은 페닐술포닐기, 페닐술피닐기 또는 페닐티오기를 나타낸다]로 표시되는 N-아미노-4-퀴놀리논유도체 또는 그의 염.
- 제3항에 있어서, R1및 R2는 각각 같거나, 상이한 것으로서 수소 원자; 할로겐 원자; 시아노기; 1∼3개의 할로겐 원자로 치환되어도 좋은 탄소수 1∼6의 알킬, 알킬술포닐, 알킬술피닐, 알킬티오 또는 알콕시기; 페닐술포닐기, 페닐술피닐기; 또는 페닐티오기를 나타내는 N-아미노-4-퀴놀리논 유도체 또는 그의 염.
- 제1항 또는 제2항에 따른 4-퀴놀리논 유도체 또는 그의 염과 약학적으로 허용되는 담체로 이루어진 의약 조성물.
- 제5항에 있어서, 순환기계 또는 기관지계 질환의 치료에 사용하기에 적합한 의약 조성물.
- 제5항에 있어서, 허혈성 심장질환, 고혈압 또는 기관지 천식의 치료에 사용하기에 적합한 의약 조성물.
- 제1항 또는 제2항의 4-퀴놀리논 유도체의 의약으로서의 사용.
- 제8항에 있어서, 의약이 순환기계 또는 기관지계 질환의 치료용 의약인 사용.
- 제8항에 있어서, 의약이 허혈성 심장질환, 고혈압 또는 기관지 천식의 치료용 의약에의 사용.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12757394 | 1994-06-09 | ||
| JP127573\1994 | 1994-06-09 | ||
| JP127573/1994 | 1994-06-09 | ||
| PCT/JP1995/001118 WO1995033726A1 (fr) | 1994-06-09 | 1995-06-06 | Derive de 4-quinolinone ou sel de ce compose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970703316A true KR970703316A (ko) | 1997-07-03 |
| KR100254106B1 KR100254106B1 (ko) | 2000-05-01 |
Family
ID=14963397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960706750A KR100254106B1 (ko) | 1994-06-09 | 1995-06-06 | 4-퀴놀리논 유도체 또는 그의 염 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5789419A (ko) |
| EP (1) | EP0764639A4 (ko) |
| JP (1) | JP3662929B2 (ko) |
| KR (1) | KR100254106B1 (ko) |
| CN (1) | CN1065529C (ko) |
| CA (1) | CA2191245A1 (ko) |
| TW (1) | TW308587B (ko) |
| WO (1) | WO1995033726A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US8722731B2 (en) | 2010-06-07 | 2014-05-13 | Novomedix, Llc | Furanyl compounds and the use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8414987D0 (en) * | 1984-06-12 | 1984-07-18 | Beecham Group Plc | Active compounds |
| JPS61165760A (ja) * | 1985-01-17 | 1986-07-26 | Canon Inc | 電子写真感光体 |
| US4971982A (en) * | 1987-07-06 | 1990-11-20 | Hoffmann-La Roche Inc. | Benzopyran derivatives |
| GB8916683D0 (en) * | 1989-07-21 | 1989-09-06 | Beecham Group Plc | Novel compounds |
| TW224941B (ko) * | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
| US5175151A (en) * | 1990-09-07 | 1992-12-29 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
| US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
| GB9112721D0 (en) * | 1991-06-13 | 1991-07-31 | Smithkline Beecham Plc | Novel treatment |
-
1995
- 1995-06-06 KR KR1019960706750A patent/KR100254106B1/ko not_active IP Right Cessation
- 1995-06-06 CA CA002191245A patent/CA2191245A1/en not_active Abandoned
- 1995-06-06 JP JP50067196A patent/JP3662929B2/ja not_active Expired - Fee Related
- 1995-06-06 WO PCT/JP1995/001118 patent/WO1995033726A1/ja not_active Application Discontinuation
- 1995-06-06 CN CN95193500A patent/CN1065529C/zh not_active Expired - Fee Related
- 1995-06-06 US US08/750,146 patent/US5789419A/en not_active Expired - Fee Related
- 1995-06-06 EP EP95920271A patent/EP0764639A4/en not_active Withdrawn
- 1995-06-08 TW TW084105816A patent/TW308587B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1065529C (zh) | 2001-05-09 |
| EP0764639A1 (en) | 1997-03-26 |
| EP0764639A4 (en) | 1997-10-01 |
| CA2191245A1 (en) | 1995-12-14 |
| WO1995033726A1 (fr) | 1995-12-14 |
| US5789419A (en) | 1998-08-04 |
| CN1150420A (zh) | 1997-05-21 |
| JP3662929B2 (ja) | 2005-06-22 |
| KR100254106B1 (ko) | 2000-05-01 |
| TW308587B (ko) | 1997-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950031074A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
| ATE271028T1 (de) | 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese | |
| DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
| KR900003127A (ko) | 강심제 | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| DE68906609D1 (de) | Dopamin-vorlaeufer. | |
| KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
| KR950016760A (ko) | 치질 치료제 | |
| KR930012698A (ko) | β-옥소-β-벤젠프로판티오아미드 유도체 | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| AU2001278708A1 (en) | Adenosine derivatives and use thereof | |
| CA2486872A1 (en) | Nf-kb inhibitors and uses thereof | |
| TR200100896T2 (tr) | İkameli propanol türevleri, imalat yöntemleri, bileşimleri içeren ilaçlar, kullanımları | |
| HUT59124A (en) | Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient | |
| KR970703316A (ko) | 4-퀴놀리논 유도체 또는 그의 염(4-quinolinone derivative or salt thereof) | |
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
| DE60019622D1 (de) | Nitroimidazolderivate und diese enthaltende diagnostische bilderzeugungsmittel | |
| ATE263183T1 (de) | A-500359-derivate | |
| EP0503079A4 (en) | Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient | |
| DE69117879D1 (de) | Arzneimittel für die Verhütung und Behandlung von Krankheiten der Kreislauforgane enthaltend Spiro-3-heteroazolidin-Verbindungen | |
| KR950032146A (ko) | 트리아졸 화합물 및 이의 제조방법 및 용도 | |
| ATE86117T1 (de) | Zusammensetzung gegen leberkrankheiten. | |
| KR930023031A (ko) | 아졸 유도체를 함유하는 항아로마타제제 | |
| DK455285A (da) | 2-pyridin-thiolderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |